Report
João Calado

BiG Research Flash Note: Biogen

Biogen is a global biopharmaceutical company, specialized in medicines for Multiple
Sclerosis and Spinal Muscular Atrophy. It is currently doing clinical trials for drugs to slow
the progression of Alzheimer’s Disease. In 2017, 68% of revenues were registered in US.

Underlying
Biogen Inc.

Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for people living with neurological and neurodegenerative diseases as well as related therapeutic adjacencies. The company's main growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis; movement disorders, including Parkinson's disease; and ophthalmology. The company's marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis.

Provider
BiG Research
BiG Research

Banco de Investimento Global, S.A. (BiG) is a privately-held, specialized financial institution, with headquarters in Lisbon, and is licensed to operate in all business areas open to the banking sector in Portugal.

BiG Research specializes in finding long term investment ideas in European and US markets.

Analysts
João Calado

Other Reports on these Companies
Other Reports from BiG Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch